Animal and translational models of SARS-CoV-2 infection and COVID-19

M. D. Johansen; A. Irving; X. Montagutelli; M. D. Tate; I. Rudloff; M. F. Nold; N. G. Hansbro; R. Y. Kim; C. Donovan; G. Liu; A. Faiz; K. R. Short; J. G. Lyons; G. W. McCaughan; M. D. Gorrell; A. Cole; C. Moreno; D. Couteur; D. Hesselson; J. Triccas; G. G. Neely; J. R. Gamble; S. J. Simpson; B. M. Saunders; B. G. Oliver; W. J. Britton; P. A. Wark; C. A. Nold-Petry; P. M. Hansbro

doi:10.1038/s41385-020-00340-z

Animal and translational models of SARS-CoV-2 infection and COVID-19

M. D. Johansen, A. Irving, X. Montagutelli, M. D. Tate, I. Rudloff, M. F. Nold, N. G. Hansbro, R. Y. Kim, C. Donovan, G. Liu, A. Faiz, K. R. Short, J. G. Lyons, G. W. McCaughan, M. D. Gorrell, A. Cole, C. Moreno, D. Couteur, D. Hesselson, J. TriccasG. G. Neely, J. R. Gamble, S. J. Simpson, B. M. Saunders, B. G. Oliver, W. J. Britton, P. A. Wark, C. A. Nold-Petry, P. M. Hansbro

Research output: Contribution to journal › Review article › peer-review

139 Scopus citations

Abstract

COVID-19 is causing a major once-in-a-century global pandemic. The scientific and clinical community is in a race to define and develop effective preventions and treatments. The major features of disease are described but clinical trials have been hampered by competing interests, small scale, lack of defined patient cohorts and defined readouts. What is needed now is head-to-head comparison of existing drugs, testing of safety including in the background of predisposing chronic diseases, and the development of new and targeted preventions and treatments. This is most efficiently achieved using representative animal models of primary infection including in the background of chronic disease with validation of findings in primary human cells and tissues. We explore and discuss the diverse animal, cell and tissue models that are being used and developed and collectively recapitulate many critical aspects of disease manifestation in humans to develop and test new preventions and treatments.

Original language	English
Pages (from-to)	877-891
Number of pages	15
Journal	Mucosal Immunology
Volume	13
Issue number	6
DOIs	https://doi.org/10.1038/s41385-020-00340-z
State	Published - 1 Nov 2020
Externally published	Yes

Access to Document

10.1038/s41385-020-00340-z

Cite this

Johansen, M. D., Irving, A., Montagutelli, X., Tate, M. D., Rudloff, I., Nold, M. F., Hansbro, N. G., Kim, R. Y., Donovan, C., Liu, G., Faiz, A., Short, K. R., Lyons, J. G., McCaughan, G. W., Gorrell, M. D., Cole, A., Moreno, C., Couteur, D., Hesselson, D., ... Hansbro, P. M. (2020). Animal and translational models of SARS-CoV-2 infection and COVID-19. Mucosal Immunology, 13(6), 877-891. https://doi.org/10.1038/s41385-020-00340-z

@article{0989e84fd0a643ce8ca4f24fe1e6b7ab,

title = "Animal and translational models of SARS-CoV-2 infection and COVID-19",

abstract = "COVID-19 is causing a major once-in-a-century global pandemic. The scientific and clinical community is in a race to define and develop effective preventions and treatments. The major features of disease are described but clinical trials have been hampered by competing interests, small scale, lack of defined patient cohorts and defined readouts. What is needed now is head-to-head comparison of existing drugs, testing of safety including in the background of predisposing chronic diseases, and the development of new and targeted preventions and treatments. This is most efficiently achieved using representative animal models of primary infection including in the background of chronic disease with validation of findings in primary human cells and tissues. We explore and discuss the diverse animal, cell and tissue models that are being used and developed and collectively recapitulate many critical aspects of disease manifestation in humans to develop and test new preventions and treatments.",

author = "Johansen, {M. D.} and A. Irving and X. Montagutelli and Tate, {M. D.} and I. Rudloff and Nold, {M. F.} and Hansbro, {N. G.} and Kim, {R. Y.} and C. Donovan and G. Liu and A. Faiz and Short, {K. R.} and Lyons, {J. G.} and McCaughan, {G. W.} and Gorrell, {M. D.} and A. Cole and C. Moreno and D. Couteur and D. Hesselson and J. Triccas and Neely, {G. G.} and Gamble, {J. R.} and Simpson, {S. J.} and Saunders, {B. M.} and Oliver, {B. G.} and Britton, {W. J.} and Wark, {P. A.} and Nold-Petry, {C. A.} and Hansbro, {P. M.}",

note = "Publisher Copyright: {\textcopyright} 2020, Society for Mucosal Immunology.",

year = "2020",

month = nov,

day = "1",

doi = "10.1038/s41385-020-00340-z",

language = "English",

volume = "13",

pages = "877--891",

journal = "Mucosal Immunology",

issn = "1933-0219",

publisher = "Elsevier B.V.",

number = "6",

}

Johansen, MD, Irving, A, Montagutelli, X, Tate, MD, Rudloff, I, Nold, MF, Hansbro, NG, Kim, RY, Donovan, C, Liu, G, Faiz, A, Short, KR, Lyons, JG, McCaughan, GW, Gorrell, MD, Cole, A, Moreno, C, Couteur, D, Hesselson, D, Triccas, J, Neely, GG, Gamble, JR, Simpson, SJ, Saunders, BM, Oliver, BG, Britton, WJ, Wark, PA, Nold-Petry, CA & Hansbro, PM 2020, 'Animal and translational models of SARS-CoV-2 infection and COVID-19', Mucosal Immunology, vol. 13, no. 6, pp. 877-891. https://doi.org/10.1038/s41385-020-00340-z

TY - JOUR

T1 - Animal and translational models of SARS-CoV-2 infection and COVID-19

AU - Johansen, M. D.

AU - Irving, A.

AU - Montagutelli, X.

AU - Tate, M. D.

AU - Rudloff, I.

AU - Nold, M. F.

AU - Hansbro, N. G.

AU - Kim, R. Y.

AU - Donovan, C.

AU - Liu, G.

AU - Faiz, A.

AU - Short, K. R.

AU - Lyons, J. G.

AU - McCaughan, G. W.

AU - Gorrell, M. D.

AU - Cole, A.

AU - Moreno, C.

AU - Couteur, D.

AU - Hesselson, D.

AU - Triccas, J.

AU - Neely, G. G.

AU - Gamble, J. R.

AU - Simpson, S. J.

AU - Saunders, B. M.

AU - Oliver, B. G.

AU - Britton, W. J.

AU - Wark, P. A.

AU - Nold-Petry, C. A.

AU - Hansbro, P. M.

PY - 2020/11/1

Y1 - 2020/11/1

N2 - COVID-19 is causing a major once-in-a-century global pandemic. The scientific and clinical community is in a race to define and develop effective preventions and treatments. The major features of disease are described but clinical trials have been hampered by competing interests, small scale, lack of defined patient cohorts and defined readouts. What is needed now is head-to-head comparison of existing drugs, testing of safety including in the background of predisposing chronic diseases, and the development of new and targeted preventions and treatments. This is most efficiently achieved using representative animal models of primary infection including in the background of chronic disease with validation of findings in primary human cells and tissues. We explore and discuss the diverse animal, cell and tissue models that are being used and developed and collectively recapitulate many critical aspects of disease manifestation in humans to develop and test new preventions and treatments.

AB - COVID-19 is causing a major once-in-a-century global pandemic. The scientific and clinical community is in a race to define and develop effective preventions and treatments. The major features of disease are described but clinical trials have been hampered by competing interests, small scale, lack of defined patient cohorts and defined readouts. What is needed now is head-to-head comparison of existing drugs, testing of safety including in the background of predisposing chronic diseases, and the development of new and targeted preventions and treatments. This is most efficiently achieved using representative animal models of primary infection including in the background of chronic disease with validation of findings in primary human cells and tissues. We explore and discuss the diverse animal, cell and tissue models that are being used and developed and collectively recapitulate many critical aspects of disease manifestation in humans to develop and test new preventions and treatments.

UR - http://www.scopus.com/inward/record.url?scp=85089666209&partnerID=8YFLogxK

U2 - 10.1038/s41385-020-00340-z

DO - 10.1038/s41385-020-00340-z

M3 - Review article

C2 - 32820248

AN - SCOPUS:85089666209

SN - 1933-0219

VL - 13

SP - 877

EP - 891

JO - Mucosal Immunology

JF - Mucosal Immunology

IS - 6

ER -

Animal and translational models of SARS-CoV-2 infection and COVID-19

Abstract

Access to Document

Fingerprint

Cite this